Atara Biotherapeutics $175 million stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175 million SEC-registered common stock and pre-funded warrants offering by Atara Biotherapeutics, Inc. Atara’s common stock is listed on the Nasdaq Global Market under the symbol “ATRA.”
Based in South San Francisco, California, Atara is a pioneer in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus, or EBV, T-cell platform to develop transformative therapies for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease.
The Davis Polk corporate team included partner Sarah K. Solum and associates Donald K. Lang, Daniel Reichert and Travis B. Mitchell. The tax team included partner Mario J. Verdolini and associate Shay Moyal. Partner Pritesh P. Shah and associate Jay Frankel provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.